John Burn-Murdoch

The fact that we're talking here less about these general one-size-fits-all medicines and more tailored to the individual.

Yeah, which is amazing.

And that raises a couple of interesting questions, though.

So something you mentioned early on is how the medical community, shall we say, has not done an amazing job of communicating these successes.

Right.

Is part of what's going on here as well that these are quiet gains?

When people stop dying of things or live a bit longer, it's not a dramatic, striking thing.

Can you talk for a minute about what the impacts of these have been at the population level?

So because the most expensive period of someone's life in terms of healthcare is those later years.

It's now almost the number of expensive late years people have has doubled.

Now, one thing that I was thinking while you were talking through this is that prevention sounds quite low tech.

But then you mentioned obesity.

And I thought, well, we've one thing that our listeners probably have heard of is the GLP-1s, these weight loss drugs.

What's your view of that?

The GLP-1s essentially a miraculous way to scale prevention.

Yeah.

Yeah.

What do they do to move the needle?

Do you think we're far away from a place where essentially GLP-1s are just universally available on the NHS or other healthcare systems?

And when I say far away, maybe 10 years.